中华外科杂志
2024年 · 第62卷第06期
中华外科杂志
- 全部
- 指南与规范
- 专家共识
- 专家论坛
- 外科论坛
- 指南解读
- 优先出版
- 论著
- 综述
According to the data released by the National Cancer Center of China, the number of primary liver cancer cases nationwide in 2022 was approximately 367,700, ranking fourth in the number of new cases of various cancers (lung, colorectal, thyroid, liver), and ranking fifth in incidence rate (lung, female breast, thyroid, colorectal, liver); In 2022, the number of deaths due to primary liver cancer was approximately 316,500, ranking second in both death count and mortality rate (lung and liver)[1-2]。 Primary liver cancer mainly includes three pathological types: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocarcinoma (cHCC-CCA). The three pathological types are quite different in pathogenesis, biological behavior, histopathology, treatment methods and prognosis, among which HCC accounts for 75% ~85% and ICC accounts for 10% ~15%[3-4]。 The term "liver cancer" in this guideline refers only to HCC.
本期目次

